



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

WITHDRAWN: Hydroxychloroquine: An Essential Drug in Dermatology and Its Controversial Use in COVID-19

D. Morgado-Carrasco,^{a,*} J. Ibaceta-Ayala,^b J. Piquero-Casals^c

^a *Servicio de Dermatología, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain*

^b *Integramédica, Redsalud, Santiago, Chile*

^c *Dermik, Clínica Dermatológica Multidisciplinar, Barcelona, Spain*

The Publisher regrets that this article is an accidental duplication of an article that has already been published, <https://doi.org/10.1016/j.ad.2022.01.012>. The duplicate article has therefore been withdrawn.

The full Elsevier Policy on Article Withdrawal can be found at <https://www.elsevier.com/about/our-business/policies/article-withdrawal>

* Corresponding author.

E-mail address: morgadodaniel8@gmail.com (D. Morgado-Carrasco).